| Autor: |
Paparizos VA; Dept. of Dermatology, Andreas Sygros Hospital, University of Athens, Greece., Kyriakis KP, Mileounis KA, Pfandl-Polydorou D, Stavrianeas NG, Vareltzidis AG, Stratigos JD |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of chemotherapy (Florence, Italy) [J Chemother] 1996 Oct; Vol. 8 (5), pp. 403-6. |
| DOI: |
10.1179/joc.1996.8.5.403 |
| Abstrakt: |
After administration of Adriamycin, bleomycin, vincristine (ABV) as palliative chemotherapy in advanced AIDS-related Kaposi's sarcoma (AIDS.KS) patients with low Karnosfsky performance scores, the authors attempted to estimate the overall biological cost/benefit relating to the disease. The authors analyzed data from 20 consecutive AIDS patients with advanced Kaposi's sarcoma presenting skin and visceral involvement treated with ABV every 3 weeks. An increased rate of infections, HIV and ABV-related side effects was observed. The performance amelioration (about 30%) was not significantly correlated with AIDS.KS clinical remission. CD4 count at baseline (p < 0.05), ABV therapy duration (p < 0.001), the achieved AIDS.KS clinical amelioration score (p < 0.01) and the improved Karnofsky score (p < 0.001) were significant predictors of life expectancy which was unrelated to the rate of side effects. The authors conclude that ABV palliative chemotherapy can assist in protracting life expectancy and improving the Karnofsky score. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
